Exelixis Stock Plunges After Mixed Q2 Earnings Report: What Investors Need to Know
Exelixis Stock Plunges After Mixed Q2 Earnings Report: What Investors Need to Know Ticker: EXEL Shares of leading biotech Exelixis (EXEL) saw a sharp decline early Thursday after the company released a mixed second-quarter earnings report. Primarily known for its oncology drug business, Exelixis struggled to meet Wall Street’s expectations, especially on its core product’s … Read more

